Residual disease activity and treatment intensification in systemic lupus erythematosus: A cross-sectional study to quantify the need for new therapies.
Ourania GiotiKaterina ChavatzaMyrto NikoloudakiSpyridon KatechisGeorge K BertsiasDimitrios T BoumpasAntonis FanouriakisPublished in: Lupus (2022)
About 40% of patients have evidence of residual disease activity and could qualify for novel treatments. Most treatment changes were triggered by active renal, joint, and skin disease, whereas the predictive value of SLEDAI-2K as a metric of disease activity was modest.